Minjuvi

Minjuvi is a brand name for the drug tafasitamab-cxix. It is a prescription medication used to treat diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, in adults. Minjuvi is typically used in combination with lenalidomide for patients who have relapsed or are refractory to at least two prior lines of systemic therapy, meaning the cancer has returned or not responded to previous treatments.

Tafasitamab is a monoclonal antibody that targets the CD19 protein, which is found on the surface of most B-cells, including lymphoma cells. By binding to CD19, Minjuvi helps the immune system identify and destroy these cancerous cells. It works by flagging the lymphoma cells for destruction by other parts of the immune system, such as natural killer cells.

The medication is administered intravenously, meaning it is given as an infusion into a vein. The dosage and schedule of Minjuvi infusions are determined by a healthcare professional based on the patient's individual condition and response to treatment. Common side effects of Minjuvi may include fatigue, diarrhea, nausea, fever, and decreased platelet count. Serious side effects can also occur, and patients should discuss any concerns with their doctor. Minjuvi is a targeted therapy that offers a treatment option for a specific group of lymphoma patients who have limited other choices.